https://www.youtube.com/watch?v=6FBIjnnT4Xs
Biophytis is a leader in the fight against sarcopenia
“Nous sommes en position de leader dans la lutte contre la sarcopénie…”
https://www.youtube.com/watch?v=6FBIjnnT4Xs
“Nous sommes en position de leader dans la lutte contre la sarcopénie…”
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
Biophytis today announces that it has submitted to the Brazilian Health Regulatory Agency (ANVISA) an amendment to the protocol of the phase 2 OBA clinical study in obesity.
Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…
Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…
Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones…
Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by…